Continuing Medical Education Program - Purchase Exams
The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for health care professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs that are approved by the FDA, as well as keep up with the recommended drug treatment for specific indications. Specifically, the content of The Medical Letter Continuing Medical Education Program covers the mechanisms of action, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosages of the drugs discussed. Participants are required to answer exam questions based on the content of The Medical Letter On Drugs and Therapeutics. Importantly, the objectives of developing the content on which the exam is based are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter's unbiased content is free of commercial influence and financial sponsorship. Our CME program is completely funded by fees paid by the exam participants. The Medical Letter Continuing Medical Education program is accredited by: ACCME, ABIM MOC, AAFP, AAPA, and ACPE.

  The Medical Letter Individual Exams — Online Only
I would like to order the following Online Per Issue Individual Exams eligible for 2 credits each: $15
per exam
1526  Drugs for Epilepsy (2 credits)   Expires 07/31/2018
1527  Safety of Long-Term PPI Use; Sarilumab (Kevzara) for Rheumatoid Arthritis; Cardiovascular Effects of Some Antidiabetic Drugs (2 credits)   Expires 08/14/2018
1528  Drugs for Asthma (2 credits)
1529  Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes; Prasterone (Intrarosa) for Dyspareunia; Safinamide (Xadago) for Parkinson's Disease; Deflazacort (Emflaza) for Duchenne Muscular Dystrophy (2 credits)
1530  Drugs for Cognitive Loss and Dementia; Tocilizumab (Actemra) for Giant Cell Arteritis (2 credits)
1531  Influenza Vaccine for 2017-2018; Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection (2 credits)
1532  Drugs for Common Bacterial Infections in Adults; Tisagenlecleucel (Kymriah) for ALL (2 credits)
1533  Guselkumab (Tremfya) for Psoriasis; Edaravone (Radicava) for ALS; Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia; Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD; Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer (2 credits)
1534  Drugs for Parkinson's Disease (2 credits)
1535  Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine; Naldemedine (Symproic) for Opioid-Induced Constipation; Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease; PARP Inhibitors for Ovarian Cancer (2 credits)
1536  Drugs for Postmenopausal Osteoporosis (2 credits)
1537  Antiviral Drugs for Seasonal Influenza 2017-2018; Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness; Fiasp - Another Insulin Aspart Formulation for Diabetes; Triptorelin (Triptodur) for Central Precocious Puberty (2 credits)
1538  Drugs for GERD and Peptic Ulcer Disease (2 credits)
1539  A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B); Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes; L-Glutamine (Endari) for Sickle Cell Disease; Neratinib (Nerlynx) for HER2-Positive Breast Cancer (2 credits)
1540  Nonopioid Drugs for Pain (2 credits)
1541  Benralizumab (Fasenra) for Severe Eosinophilic Asthma; Once-Monthly Subcutaneous Buprenorphine (Sublocade) for Opioid Use Disorder; Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis; Haegarda - A Subcutaneous C1 Esterase Inhibitor for Prevention of Hereditary Angioedema (2 credits)
1542  Drugs for Treatment and Prevention of Venous Thromboembolism (2 credits)
1543  Delafloxacin (Baxdela) - A New Fluoroquinolone Antibiotic; Secnidazole (Solosec) for Bacterial Vaginosis; Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy; Dapagliflozin/Saxagliptin (Qtern) for Type 2 Diabetes (2 credits)
1544  Opioids for Pain (2 credits)
1545  Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia; Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV; Ertugliflozin for Type 2 Diabetes; Nebulized Glycopyrrolate (Lonhala Magnair) for COPD (2 credits)
1546  Adult Immunization (2 credits)
1547  Auvi-Q Epinephrine Auto-Injector for Infants and Toddlers; Clenpiq - A Low-Volume Sodium Picosulfate-Based Colonoscopy Preparation; Trelegy Ellipta - A Three-Drug Inhaler for COPD; Clarithromycin in Patients with Coronary Artery Disease; Restrictions on Essure (2 credits)
1548  Diet, Drugs, Devices, and Surgery for Weight Management (2 credits)
1549  Andexxa - An Antidote for Apixaban and Rivaroxaban; Erenumab (Aimovig) for Migraine Prevention; Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection; A Potentially Fatal Immune Reaction to Lamotrigine; Pitavastatin Magnesium (Zypitamag) for Hyperlipidemia (2 credits)
1550  Drugs for Inflammatory Bowel Disease (2 credits)
1551  Lofexidine (Lucemyra) for Opioid Withdrawal; Two New Drugs for Glaucoma; Baricitinib (Olumiant) for Rheumatoid Arthritis; Firvanq - Vancomycin Oral Solution (2 credits)